Manufacturing News of Note—Merck & Co., Just - Evotech to share specialized biologics space; DBL buys GSK cream line in Bangladesh

A closeup of a stock market ticker

>  Merck & Co will pay Seattle-based Just – Evotec Biologics $15 million upfront to use excess capacity at a biologics facility the company is building in Redmond, Washington. Story

> GBA Group Pharma has doubled the size of its clinical supply facilities in Vienna ahead of Brexit, it says. Release

> DBL Pharmaceuticals says it has a deal to acquire the cream and ointment manufacturing line of GlaxoSmithKline Bangladesh with plans of reintroducing the products that GSK made there before exiting the country. Story

> Helixmith Co. and Genopis say they will launch a contract manufacturing operation to manufacture plasmid DNA for clients. Release

> Medivant Health is building a 33,000-square-foot generic drug manufacturing facility in Chandler, Arizona, to address drug shortages. Story

Suggested Articles

CureVac and Tesla are teaming up to produce the German vaccine maker's molecular RNA printers, Tesla CEO Elon Musk tweeted Thursday.

The FDA knocked a California compounding pharmacy facility for a suite of sanitary concerns, including the presence of ants in the plant.

Merck Animal Health will plow $100 million into its DeSoto, Kansas, plant to scale up production of animal vaccines.